Pain intensity (number of people with ≥ 50% improvement) · adults with chronic pain
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Symptom relief · Patients with COVID‐19
1 finding from 1 review
Intervention not reported
Quality of life · Patients with COVID‐19
1 finding from 1 review
Intervention not reported
Symptom burden · Patients with COVID‐19
1 finding from 1 review
Intervention not reported
Satisfaction of patients · Patients with COVID‐19
1 finding from 1 review
Intervention not reported
Satisfaction of caregivers · Patients with COVID‐19
1 finding from 1 review
Intervention not reported
Satisfaction of relatives · Patients with COVID‐19
1 finding from 1 review
Intervention not reported
Serious adverse events · Patients with COVID‐19
1 finding from 1 review
Intervention not reported
Grade 3 to 4 adverse events · Patients with COVID‐19
1 finding from 1 review
Intervention not reported
N/A: Not applicable · Patients with COVID‐19
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Symptoms of delirium within 24 hoursa · terminally ill adults with delirium
Summary of findings: haloperidol showed no clear difference in symptoms of delirium within 24 hoursa compared with placebo (low certainty).
1 finding from 1 review
Adverse events including extrapyramidal effects · terminally ill adults with delirium
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Symptoms of delirium within 24 hoursa · terminally ill adults with delirium
It is very uncertain whether summary of findings: haloperidol changes symptoms of delirium within 24 hoursa compared with olanzapine (very low certainty).
1 finding from 1 review
Symptoms of delirium between 24 and 48 hoursa · terminally ill adults with delirium
It is very uncertain whether summary of findings: haloperidol changes symptoms of delirium between 24 and 48 hoursa compared with olanzapine (very low certainty).
1 finding from 1 review
Specific behaviour ‐ agitation · terminally ill adults with delirium
The review found no eligible studies for this question.
2 findings from 1 review
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found
Adverse events including extrapyramidal effects · terminally ill adults with delirium
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Symptoms of delirium within 24 hoursa · terminally ill adults with delirium
Summary of findings: risperidone showed no clear difference in symptoms of delirium within 24 hoursa compared with placebo (low certainty).
1 finding from 1 review
Symptoms of delirium between 24 and 48 hoursa · terminally ill adults with delirium
Summary of findings: risperidone showed no clear difference in symptoms of delirium between 24 and 48 hoursa compared with placebo (low certainty).
1 finding from 1 review
Specific behaviour ‐ agitation · terminally ill adults with delirium
The review found no eligible studies for this question.
2 findings from 1 review
Symptoms of delirium between 24 and 48 hoursa · terminally ill adults with delirium
Summary of findings: haloperidol showed no clear difference in symptoms of delirium between 24 and 48 hoursa compared with placebo (low certainty).
1 finding from 1 review